# US 2008/0075769 A1 · Psychostimulant containing pharmaceutical composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075769 A1
- Document ID: US20080075769A1
- Status: Published application
- Kind: A1
- Application number: 11/710,170
- Filed: 2007-02-23
- Published: 2008-03-27
- Earliest claimed: 2004-08-23
- Assignees: PEJO Iserlohn Heilmittel und Diaet GmbH & Co. KG
- Inventors: Reiner Poestges; Bernd Schneider; Richard Ammer
- Web page: https://patentgrep.com/patent/US20080075769A1

## CPC

- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to a psychostimulant containing pharmaceutical composition comprising an enteric coating and showing a sustained release of said psychostimulant in vivo. The invention is further directed to the use of said pharmaceutical composition in the treatment of the Attention Deficit Hyperactivity Disorder (ADHD) and comorbidities, narcolepsy, fatigue and/or cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome or oncological diseases. Additionally, the present invention provides a method for the manufacture of said pharmaceutical composition.

## Claims

### Claim 1

A method for the manufacture of a pharmaceutical composition comprising two distinct components, the first component containing an initial dosage of a psychostimulant and the second component containing a second dosage of said psychostimulant, wherein the release of said second dosage is modified,
characterized in that the release of said second dosage is modified by an enteric coating comprising (co-)polymers of (meth)acrylic acid and/or (meth)acrylate containing carboxyl groups, thereby causing a sustained release of said second dosage of the psychostimulant in vivo, comprising the steps of:
a) manufacturing the first component by:
providing spheres,
preparing a liquid containing a psychostimulant,
coating the spheres with said liquid, and
drying the coated spheres;
b) manufacturing the second component by:
providing spheres manufactured in accordance with step a),
preparing a liquid suitable for providing an enteric coating on said spheres, the liquid containing (co-)polymers of (meth)acrylic acid and/or (meth)acrylate having carboxyl groups and an alkaline agent,
coating the spheres with said liquid, and
drying the coated spheres.

### Claim 2 (depends on 1)

The method of claim 1, wherein steps a) and/or b) further comprise the step of mixing the spheres with a mixture of micronised talc and colloidal anhydrous silica and/or sieving the spheres obtained.

### Claim 3 (depends on 1)

The method of claim 1, wherein components a) and b) are incorporated in a hard gelatine capsule or sachet.

### Claim 4 (depends on 1)

The method of claim 1, wherein the alkaline agent is selected from NaOH and KOH.

### Claim 5 (depends on 1)

The method of claim 1, wherein the alkaline agent is added to the liquid in an amount sufficient to achieve a neutralisation of 2-10, preferably 3-8, most preferably about 6% of said carboxyl groups.

### Claim 6 (depends on 1)

The method of claim 1, wherein the first and the second component of the pharmaceutical composition contain identical amounts of said psychostimulant.

### Claim 7 (depends on 1)

A pharmaceutical composition obtainable by the method of claim 1.

### Claim 8 (depends on 6, 7)

The pharmaceutical composition of claim 7 obtainable by the method of claim 6, wherein the in vivo release of the composition is showing a first (Cmax1) and a second peak (Cmax2) plasma concentration, wherein Cmax1>Cmax2.

### Claim 9 (depends on 7)

The pharmaceutical composition of claim 7, wherein a sustained release of said second dosage of psychostimulant is caused in the fed condition in vivo.

### Claim 10 (depends on 7)

The pharmaceutical composition of claim 7, wherein the second component comprises an enteric coating based on a methacrylic acid copolymer.

### Claim 11 (depends on 7)

The pharmaceutical composition of claim 7, wherein the psychostimulant is selected from the group consisting of amphetamine, metamphetamine, amphetaminil, fenetylline, methylphenidate and prolintane or a pharmaceutically acceptable salt thereof, an enantiomer or mixtures thereof, or mixtures of said ingredients.

### Claim 12 (depends on 7)

The pharmaceutical composition of claim 7, wherein the first and the second component is present in spherical form, preferably in pellet form.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the first component comprises spheres on which the psychostimulant contained in a liquid is coated.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the liquid is a suspension and is containing one or more of the following ingredients:
Povidone K 30,
Talc, micronised,
Purified water,
2-Propanol, and
Methylphenidate.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the spheres are mixed with a mixture of micronised talc and colloidal anhydrous silica (preferably 50:50 w/w) subsequent to the step of coating the suspension on the spheres.

### Claim 16 (depends on 14)

The pharmaceutical composition of claim 14, wherein the first component is comprising the following manufacturing formula in parts per weight:
Methylphenidate hydrochloride 0.1800-0.3000
Sugar spheres 3.5000-5.0000
Povidone K 30 0.0100-0.0300
Talc, micronised 0.0400-0.0500
Purified water 1.0000-2.0000
2-Propanol 0.1000-0.2000
Mixture of micronised talc and colloidal anhydrous silica 0.0010-0.0040

### Claim 17 (depends on 14)

The pharmaceutical composition of claim 14, wherein the first component is comprising the following manufacturing formula in parts per weight:
Methylphenidate hydrochloride 0.4000-0.6000
Sugar spheres 1.5000-5.0000
Povidone K 30 0.0300-0.0500
Talc, micronised 0.0800-0.1000
Purified water 2.5000-2.8000
2-Propanol 0.2000-0.3000
Mixture of micronised talc and colloidal anhydrous silica 0.0020-0.0030

### Claim 18 (depends on 7, 13)

The pharmaceutical composition of claim 7, wherein for the manufacturing of the second component, the enteric coating is coated on the first component as defined in claim 13, contained in a suspension comprising one or more of the following ingredients:
Eudragit L 30 D-55,
Sodium hydroxide,
Talc, micronised,
Triethyl citrate,
Simeticone emulsion,
Purified water, and optionally
a colorant.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the second component is comprising the following manufacturing formula in parts per weight:
Methylphenidate hydrochloride 0.1500-0.3000
Sugar spheres 2.5000-4.0000
Povidone K 30 0.0150-0.3000
Talc, micronised 0.0300-0.0500
Purified water 1.0000-2.0000
2-Propanol 0.1000-0.2000
Eudragit L 30 D-55 3.0000-4.0000
Sodium hydroxide 15% 0.1000-0.1500
Talc, micronised 0.5000-0.6000
Triethyl citrate 0.1000-0.2000
Indigotine lacquer (E 132) 0.0060-0.0100
Sinieticone emulsion 0.0100-0.0200
Purified water 2.0000-3.0000
Mixture of micronised talc and colloidal anhydrous silica (50:50) 0.0020-0.0030

### Claim 20 (depends on 18)

The pharmaceutical composition of claim 18, wherein the second component is comprising the following manufacturing formula in parts per weight:
Methylphenidate hydrochloride 0.4000-0.6000
Sugar spheres 2.5000-5.0000
Povidone K 30 0.0400-0.0500
Talc, micronised 0.0900-0.1000
Purified water 2.0000-3.0000
2-Propanol 0.2000-0.3000
Eudragit L 30 D-55 3.0000-4.0000
Sodium hydroxide 15% 0.1000-0.1500
Talc, micronised 0.5000-0.6000
Triethyl citrate 0.1000-0.2000
Indigotine lacquer (E 132) 0.0060-0.0100
Simeticone emulsion 0.0100-0.0200
Purified water 2.0000-3.0000
Mixture of micronised talc and colloidal anhydrous silica 0.0020-0.0040

### Claim 21 (depends on 7)

The pharmaceutical composition of claim 7, wherein the first and second components are incorporated in a capsule, preferably a hard gelatine capsule, or in a sachet.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the overall content of methylphenidate per capsule is 5-60 mg, preferably 10, 20, 30, 40 or 60 mg.

### Claim 23 (depends on 7)

The pharmaceutical composition of claim 7, wherein the psychostimulant is methylphenidate or a pharmaceutically acceptable salt thereof, an enantiomer or mixtures thereof, and the mean in vitro dissolution profile in aqueous media of pH 1-3, preferably 1.2, is such that 80-100% of methylphenidate contained in the first component are released within 30, preferably 20, more preferably 15 min. following administration, and 80-100% of methylphenidate contained in the second component are released within 30, preferably 20, more preferably 15 min. following administration in a second media having a pH of 6.5-7.2, preferably 6.8.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein the in vivo release of the pharmaceutical composition essentially is a sustained release, wherein the main peak plasma concentration of methylphenidate is reached between 0.5 and 5, preferably between 1 and 4, most preferably at about 2.5 hours following administration of said pharmaceutical composition.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the plasma concentration at about 8 h following administration of the pharmaceutical composition is between 30-80% of the main peak plasma concentration of methylphenidate.

### Claim 26 (depends on 23)

The pharmaceutical composition of claim 23, wherein the in vivo release of the pharmaceutical composition essentially is a sustained release, and there is a highest peak plasma concentration between 1 and 4 h after administration of the pharmaceutical composition.

### Claim 27 (depends on 7)

Use of a pharmaceutical composition of claim 7 for the manufacture of a medicament for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and comorbidities, narcolepsy, fatigue and/or cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome or oncological diseases.
